N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Completes initial testing on loading its Nuvec treatment with two generic siRNA probes at the same time. siRNA can prevent cells from communicating, potentially preventing cancer cells from replicating. N4 are now undertaking experiments using siRNA sequences against known oncology targets. This includes in vitro using a lung cancer cell line and, after that, in vivo studies in mice. Chief Executive Officer Nigel Theobald said: "We have now identified a very strong commercial point of difference for Nuvec in that it can be successfully loaded with at least two siRNA genes".
Current stock price: 1.60 pence each, up 3.2%
12-month change: down 81%
By Chris Dorrell; chrisdorrell@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
N4 Pharma Plc (N4P)